XML 27 R15.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans

9 Months Ended

Sep. 30, 2025

Defined Benefit Plan [Abstract]

Employee Benefit Plans

Note 7. Employee Benefit Plans

401(k) Plan:

The Company provides a deferred salary reduction plan (“Plan”) under Section 401(k) of the Internal Revenue Code covering substantially all employees. After 90 days of service, the Company matches 100% of employee contributions up to 3% of compensation and 50% of employee contributions on the next 2% of compensation. The Company’s contribution to the Plan for the three and nine month periods ending September 30, 2025, was $545 thousand and $1.6 million, respectively. The Company’s contribution to the Plan for the three and nine months ended September 30, 2024, was $504 thousand and $1.5 million, respectively.

Equity Incentive Plans:

The Compensation Committee of the Company’s board of directors may grant or award eligible participants stock options, restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards or any combination of awards (collectively referred to herein as "Rights"). At September 30, 2025, the Company had one active equity incentive plan available for future grants, the Omnibus Incentive Plan, which was approved on May 22, 2025, and has 1,682,333 Rights available for future grants or awards.

The Company’s 2015 Stock Incentive Plan expired on March 23, 2025, and has no rights issued or outstanding at September 30, 2025.

Stock Options:

A summary of the status of stock option plans is presented in the following table:


				Weighted
				Average
				Exercisable
		Number		Price
Outstanding at December 31, 2024		10,148		$	15.05
Granted		—			—
Exercised		(10,148)			15.05
Forfeited		—			—
Outstanding at September 30, 2025		—		$	—

At September 30, 2025, there are no outstanding stock options.

The Company did not recognize any stock option-based compensation expense during the three and nine months ended September 30, 2025, and 2024, respectively, as all stock options issued are fully vested, and no future compensation cost will be recognized related to nonvested stock-based compensation arrangements granted under the Plan.

Stock options of 5,945 and 10,148 shares were exercised during the three and nine month periods ended September 30, 2025, respectively. Stock options of 1,692 and 6,192 shares were exercised during the three and nine month periods ended September 30, 2024, respectively. The income tax benefit recognized for the exercise of options during the three and nine months ended September 30, 2025, was a benefit of $10 and $14 thousand, and for the three and nine months ended September 30, 2024, was a benefit of $0 and $14 thousand.

The intrinsic value of options exercised during the three and nine months ended September 30, 2025, was $129 thousand and $206 thousand, respectively. The intrinsic value of options exercised during the three and nine months ended September 30, 2024, was $15 thousand and $69 thousand, respectively. No stock options are outstanding or exercisable at September 30, 2025. Cash received from options exercised under all share-based payment arrangements for the nine months ended September 30, 2025, was $154 thousand.

Restricted Stock Awards:

A summary of the activity of the Company’s unvested restricted stock awards for the period ended September 30, 2025, is presented below:


				Weighted
				Average
				Grant-Date
		Number		Fair Value
Outstanding at December 31, 2024		195,859		$	23.02
Granted		105,075			35.29
Vested		(56,932)			22.37
Forfeited/expired		(3,762)			27.38
Outstanding at September 30, 2025		240,240		$	28.47

The Company measures the fair value of restricted stock awards based on the price of the Company’s common stock on the grant date, and compensation expense is recorded over the vesting period. The compensation expense for restricted stock awards during the three and nine months ended September 30, 2025, was $404 thousand and $1.6 million, respectively, and was $372 thousand and $1.3 million, during the three and nine months ended September 30, 2024, respectively. As of September 30, 2025, there was $3.5 million of unrecognized compensation cost related to non-vested restricted stock awards granted under the plan. The cost is expected to be recognized over a weighted average period of 2.35 years. The grant-date fair value of restricted stock awards vested was $1.3 million for the nine months ended September 30, 2025.

Stock Appreciation Rights (“SARs”):

At September 30, 2025, there are no outstanding SARs.

There was no SARs compensation expense for the three and nine months ended September 30, 2025, and $41 thousand and $7 thousand for the three and nine months ended September 30, 2024.